Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bambuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.97 |
| ▸ | BCHE | P06276 | 6/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | ACHE | P22303 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bambuterol SCHEMBL4432 | 0.99 | BCHE (1.00) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Bambuterol SCHEMBL13923751 | 0.99 | BCHE (1.00) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Bambuterol SCHEMBL4431 | 0.99 | BCHE (1.00) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Bambuterol SCHEMBL1649102 | 0.96 | BCHE (0.95) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Bambuterol SCHEMBL3713500 | 0.95 | BCHE (0.92) | BCHECYP2D6ACHEADRB2KCNH2 | |
| SCHEMBL15790253 | 0.94 | BCHE (0.90) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Bambuterol SCHEMBL21645369 | 0.94 | BCHE (0.90) | BCHECYP2D6ACHEADRB2KCNH2 | |
| Hydrochloric Acid SCHEMBL11123610 | 0.94 | BCHE (0.85) | BCHECYP2D6ACHEADRB2KCNH2 | |
| SCHEMBL21674420 | 0.92 | BCHE (0.88) | BCHECYP2D6ACHEADRB2KCNH2 | |
| SCHEMBL15790471 | 0.91 | BCHE (0.85) | BCHECYP2D6ACHEADRB2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649960-A1 | USE OF LONG-ACTING ß2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | Hong Kong Sxmeterol Pharmaceutical Co., Limited (HK) | 2025-11-19 | — | — | EP | claimed |
| WO-2024160057-A1 | USE OF LONG-ACTING β2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | 上海市第十人民医院 | 2024-08-08 | — | — | WO | claimed |
| CN-117586152-A | Preparation method of bambuterol hydrochloride | 黑龙江乌苏里江制药有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| CN-115141121-A | Method for synthesizing bambuterol hydrochloride impurity B | 宏冠生物药业有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-114129527-A | Miniature tablet and preparation method and preparation thereof | 北京微智瑞医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-109942462-B | Synthesis process of bambuterol hydrochloride | 宏冠生物药业有限公司 | 2022-01-14 | — | — | CN | claimed |
| CN-110898003-A | Novel bambuterol hydrochloride oral solution and preparation method thereof | 岳阳新华达制药有限公司 | 2020-03-24 | — | — | CN | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| EP-2431028-B1 | FAST-DISSOLVING ORAL FILM FOR EFFECTIVELY CONCEALING UNPLEASANT TASTES | CHABIO & DIOSTECH CO LTD (KR) | 2017-07-12 | — | — | EP | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001032166-A1 | NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| EP-0717616-B1 | PROCESS FOR CONDITIONING SUBSTANCES | ASTRAZENECA AB (SE) | 2001-03-21 | — | — | EP | claimed |
| US-5709884-A | USING WATER VAPOR; PROCESS CONTROL | ASTRA AKTIEBOLAG (SE) | 1998-01-20 | — | — | US | claimed |
| US-5562923-A | MICRONIZED PHARMACEUTICALLY INHALABLE SUBSTANCES | AKTIEBOLAGET ASTRA (SE) | 1996-10-08 | — | — | US | claimed |
| EP-0717616-A1 | PROCESS FOR CONDITIONING SUBSTANCES | Astra Aktiebolag (SE) | 1996-06-26 | — | — | EP | claimed |
| EP-0580648-B1 | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES | ASTRA AB (SE) | 1996-05-08 | — | — | EP | claimed |
| WO-1995005805-A1 | PROCESS FOR CONDITIONING SUBSTANCES | ASTRA AKTIEBOLAG (SE) | 1995-03-02 | — | — | WO | claimed |
| EP-0508969-A1 | Process for conditioning of water-soluble substances | Astra Aktiebolag (SE) | 1992-10-14 | — | — | EP | claimed |